ANGIODYNAMICS INC

AngioDynamics Inc. reported significant strategic changes, including the divestment of its dialysis and BioSentry businesses in June 2023, and its PICC and Midline businesses in February 2024. The company also discontinued its RadioFrequency Ablation and Syntrax product lines. Positively, its NanoKnife System received expanded FDA 510(k) clearance for prostate tissue ablation in December 2024 and BSI approval for the MDR CE mark for expanded indications in February 2026. As of November 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $436.3 million.

AngioDynamics announced record financial results for fiscal year 2026, with pro forma net sales of $320.2 million, up 9.4% year-over-year. The Med Tech segment achieved 18.4% growth, marking its seventh consecutive quarter of double-digit growth and contributing to positive adjusted EBITDA of $13.2 million. The company also reported significant clinical and regulatory milestones for its NanoKnife, AlphaVac, and AngioVac systems, and provided positive fiscal year 2027 guidance.

AngioDynamics, Inc. has initiated a patent infringement lawsuit against Endovascular Engineering, Inc. (E2) in the United States District Court for the District of Delaware. The complaint alleges that E2's Hēlo Thrombectomy System infringes several of AngioDynamics' registered patents, specifically those related to its self-expanding funnel technology. AngioDynamics is seeking both damages and equitable relief, emphasizing its commitment to protecting its intellectual property rights to support continued innovation.